Skip to content
Search

Latest Stories

Boots transfers £4.8 Billion Pension Plan to Legal & General

Boots transfers £4.8 Billion Pension Plan to Legal & General

Boots also brings in an additional payment of around £500m to the scheme

Walgreens Boots Alliance (WBA), which owns the retail pharmacy chain Boots in the UK, has signed a buy-in deal with financial services company Legal & General, transferring its £4.8 billion ($6 billion) pension plan to the latter.


In a release issued on Friday, the company said that the deal is the “largest single transaction of its kind,” in the UK and insures all 53,000 members in the Boots Pension Scheme.

The company said it was the best options to “safeguard members’ benefit against market uncertainty, improved life expectancies and other risks”.

Boots is also bringing in an additional payment of around £500m to the scheme, in addition to the sum (£170m) it has already committed.

Boots Pension Scheme trustee chair Alan Baker is optimistic that this agreement with Legal & General will give “added protection to our members’ long-term benefits by removing market uncertainty and other financial exposures.”

"The scheme will not be reliant on Boots to pay benefits to members and pensions will be protected for decades to come," he added.

L&G will assume the responsibility for issuing individual annuity policies to scheme members and paying benefits directly to them.

However, the business said will take up to two years to complete the process of moving the members, after which it will bear most of the scheme’s economic risk.

Boots UK managing director Seb James commented that they “have fully secured the benefits of all members with a highly respected insurer” and this will provide “greater certainty to both the scheme members and to Boots and is an excellent outcome for both parties."

Describing the deal as their “largest ever single transaction”, Legal & General CEO Kail said it was a proof to their “long-standing relationship with the client.

Earlier, the WBA had agreed to guarantee the scheme but the agreement has been terminated and replaced with a smaller, temporary guarantee.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less